Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
611 (anti-IL-4R alpha antibody) in moderate to severe atopic dermatitis
NCT06173284Phase 3Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jan 2024
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of SSGJ-611 in atopic dermatitis (AD), sponsored by 3S Guojian Pharmaceutical. Started Jan 2024; status: completed.
02
Drugs
SSGJ-611
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06173284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06173284.